Sensei Biotherapeutics (SNSE) Announces Addition to the Nasdaq Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
December 13, 2021 4:01 PM ESTBOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to market open on Monday, December 20, 2021.
The NBI was launched in 1993 and includes securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceutical companies. Companies in the NBI must meet eligibility requirements, including average daily trading volume, minimum market... More
